23 Feb Bellicum
Rick Fair, CEO
Bellicum is a clinical-stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum currently has three product candidates: BPX-601, a GoCAR-T® targeting PSCA for the treatment of pancreatic cancer; BPX-603, a GoCAR-T targeting tumors expressing HER2; and a GoCAR-NK program targeting BCMA for the treatment of multiple myeloma.